Ashley Euan A. 4

What Happened

• Ashley Euan, a director of DexCom, received a grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award was recorded at $0.00 per share (a typical equity grant, not a cash purchase or sale). Each RSU represents a contingent right to receive one share of DexCom common stock upon settlement.

Key Details

• Transaction date: 2026-05-28 (reported on Form 4 filed 2026-06-01).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 5,565 RSUs; reported price $0.00; initial reported value $0.
• Vesting: 100% of this RSU award vests on the earlier of (a) the one-year anniversary of the grant date or (b) DexCom’s 2027 Annual Meeting of Stockholders (i.e., likely to vest within one year).
• Shares owned after transaction: Filing notes a total of 12,731 unvested RSUs included in reported holdings — 5,565 from this grant and 7,166 from an Oct 24, 2025 grant that vest through Oct 24, 2028. (The filing’s total share ownership figure beyond unvested RSUs was not provided here.)
• Footnotes: F1 explains vesting timing and that each RSU converts to one share upon settlement; F2 breaks out the 12,731 unvested RSUs (5,565 new; 7,166 prior).
• Timeliness: Form filed June 1, 2026 covering the May 28, 2026 grant; no late filing flag indicated.

Context

• This is a standard equity compensation award to a director, not an open-market purchase or sale. RSUs are contingent (they become actual shares only after vesting and settlement) and thus do not immediately increase tradable share count.
• Such grants are routine for executive/director compensation and do not by themselves indicate a buy or sell signal.